Differential binding patterns of monoclonal antibody 2C4 to the ErbB3–p185her2/neu and the EGFR–p185her2/neu complexes
Open Access
- 11 February 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 27 (27), 3870-3874
- https://doi.org/10.1038/onc.2008.13
Abstract
2C4 (Pertuzumab, Omnitarg) is a monoclonal antibody targeting p185her2/neu, which is overexpressed in 30% of invasive breast cancer. 2C4 is currently in phase II clinical trials for several types of cancers. This antibody has been reported to disrupt the association between p185her2/neu and ErbB3. In our studies of epidermal growth factor receptor (EGFR)–p185her2/neu heterodimerization, we noted that 2C4 formed associations with the EGFR–p185her2/neu receptor complex. Our data argue against 2C4 as a universal heterodimerization blocker for p185her2/neu, but indicate that cocktails of monoclonal antibodies binding distinct interaction surfaces of p185her2/neu will emerge as the most potent targeted therapy.Keywords
This publication has 32 references indexed in Scilit:
- Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Nature, 2007
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- EGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain DimerizationMolecular Cell, 2003
- Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular DomainsCell, 2002
- Structure of the Extracellular Region of HER3 Reveals an Interdomain TetherScience, 2002
- Disabling Receptor Ensembles with Rationally Designed Interface PeptidomimeticsJournal of Biological Chemistry, 2002
- SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modelingElectrophoresis, 1997
- Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor functionCell, 1990
- Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodiesCell, 1985